植物生物反应器生产绿色疫苗研究进展

植物生物反应器为人类提供了更为安全的疫苗生产体系。研究显示植物源性的绿色疫苗确实能诱导动物和人产生粘膜和全身性免疫应答。与传统疫苗相比,可食疫苗更简单、安全、稳定、经济和卫生。本文综述了绿色疫苗基因工程的研究及进展,并对潜在的问题及对策略进行了探讨。     

转基因植物作为生物反应器在畜禽疫苗生产中的应用

植物生物反应器为人类提供了更为安全的疫苗生产"车间"。与传统疫苗相比,转基因植物疫苗具有更安全、稳定、经济和使用方便等优点。综述了转基因植物在畜禽疫苗应用方面的研究进展,并对存在的问题及解决方法进行了探讨。     

植物口服疫苗的动物和临床实验*

利用转基因植物生产亚单位疫苗用于口服主动免疫具有安全、廉价和方便等优点。植物可以正确地表达细菌和病毒抗原基因,对动物及人类的临床实验研究表明：食用表达某种抗原的转基因植物可在实验动物或人群体内激起系统免疫和粘膜免疫,产生相应的特异性抗体,这些结果表明了植物口服疫苗的可行性。此外,在治疗自身免疫疾病以及癌症等方面,植物口服疫苗也具有值得关注的作用。     

转基因植物疫苗研究进展

疫苗是当今世界上控制及预防疾病发生的有效方法,利用植物作为生物反应器生产转基因疫苗,成本低廉,方便安全等特点,被认为新型疫苗的研究热点。从4个方面综述了转基因疫苗的研究概况,分析了其优点及不足,并对其未来的发展进行了展望。     

利用转基因植物生产口服疫苗的研究现状

本文概述了利用转基因植物生产口服疫苗的研究现状。分别对转基因植物生产口服疫苗的优点、作用原理、研究方法、已研究的口服疫苗及问题和前景进行了介绍。     

利用转基因植物生产口服疫苗的研究现状

本文概述了利用转基因植物生产口服疫苗的研究现状,分别对转基因植物生产口服疫苗的优点、作用原理,研究方法,已研究的口服疫苗及问题和前景进行了介绍。     

转基因植物疫苗研究策略

利用转基因植物作为生物反应器生产疫苗受到越来越多的关注。对转基因植物疫苗的研究、生产策略进行了介绍 ,重点对提高植物疫苗表达所采用的生物技术策略进行综述 ,探讨转基因植物疫苗的发展及面临的问题。     

转基因植物疫苗免疫原基因表达研究概述

近年来 ,随着基因工程、蛋白质工程以及免疫学理论与技术的迅速发展 ,以开发新型高效疫苗为目标的新的研究领域异常活跃 ,基因工程亚单位疫苗、基因缺失疫苗、重组病毒活载体疫苗、核酸疫苗各展风姿 ,但这些系统存在设备复杂 ,成本高 ,免疫原性较差和外源微生物污染的缺陷 .为克服上述缺陷 ,进入 2 0世纪 90年代 ,以植物为生物反应器的疫苗研究策略迅速发展 ,短短几年以植物为生物反应器的可食性疫苗取得了可喜的进展 ,这些进展也开辟了植物生物技术革命的新天地 .1　转基因植物基因疫苗研究原理和策略利用转基因植物生产疫苗 ,是将抗原基因…     

转基因植物疫苗的研究进展

近些年,随着遗传技术和植物基因工程的发展进步,疫苗（亚单位疫苗、活载体疫苗和核酸疫苗等）的研究迅速发展起来。尤其是利用转基因植物技术生产植物疫苗的研究受到了广泛的关注,在转基因植物（蔬菜、水果、农作物）的可食用部位表达抗原生产人或动物治疗用重组蛋白和疫苗的技术为可食性疫苗的研制开辟了新途径,展现了诱人的开发前景。植物来源的疫苗具有很多优势,如生产成本低、易于保存、免疫接种方便、甚至不需提取纯化等处理而直接食用。目前已有很多转基因植物疫苗产品投入开发和生产。文章综述了近几年转基因植物疫苗在表达系统、生产、生物安全／管理、公众健康等方面的研究进展,对转基因植物疫苗存在的问题进行了分析,并对其研究前景提出了展望。     

转基因植物作为生物反应器在疫苗生产中的应用

对转基因植物生产口服疫苗的发展、优点与作用机理、方法原理进行介绍,概述当前各种转基因植物疫苗的研究现状,指出了转基因植物疫苗研究面临的问题与前景 。     

Induction of anti-inflammatory immune response by an adenovirus vector encoding 11 tandem repeats of Abeta1-6: toward safer and effective vaccines against Alzheimer's disease

Induction of an immune response to amyloid beta-protein (Abeta) is effective in treating animal models of Alzheimer's disease. Human clinical trials of vaccination with synthetic Abeta (AN1792), however, were halted due to brain inflammation, presumably induced by T cell-mediated immune responses. We have developed an adenovirus vector as a "possibly safer" vaccine. Here, we show that an adenovirus vector encoding 11 tandem repeats of Abeta1-6 can induce an immune response against amyloid beta-protein. Much higher titers against amyloid beta-protein were observed when an adenovirus vector encoding GM-CSF was co-administered. Immunoglobulin isotyping revealed a predominant IgG1 response, indicating anti-inflammatory Th2 type. Immunohistochemical analysis revealed no inflammation-related pathology in the brain of mice immunized with the adenovirus vector. Induced antibodies strongly reacted with amyloid plaques in the brain, demonstrating functional activity of the antibodies. Thus, the adenovirus vector encoding 11 tandem repeats of Abeta1-6 may be a safer alterative to peptide-based vaccines.     

疫苗诱导机体免疫应答机制研究

人类接种疫苗已有200多年的历史,疫苗的应用使得历史上流行的多种传染病得以消灭或控制,挽救了无数人的生命。疫苗免疫机制是全世界疫苗研究者亟待解决的问题。对疫苗免疫机制的一些新认识,极大地促进了疫苗研发。对疫苗天然免疫机制的揭示,在疫苗株的筛选、疫苗免疫效果预测等方面展现了巨大的应用价值。某些疫苗在接种后存在的低应答与无应答现象,在对其免疫机制的探索中得到了解释。此外,对疫苗佐剂免疫机制的揭示,加速了新型疫苗佐剂的研发与应用。对疫苗免疫机制研究中的一些新进展进行了综述。     

Counterpoint. Cancer vaccines: single-epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine

Anti-idiotype (Id) vaccine therapy has been tested and shown to be effective, in several animal models, for triggering the immune system to induce specific and protective immunity against bacterial, viral and parasitic infections. The administration of anti-Id antibodies as surrogate tumor-associated antigens (TAA) also represents another potential application of the concept of the Id network. Limited experience in human trials using anti-Id to stimulate immunity against tumors has shown promising results. In this “counterpoint” article, we discuss our own findings showing the potential of anti-Id antibody vaccines to be novel therapeutic approaches to various human cancers and also discuss where anti-Id vaccines may perform better than traditional multiple-epitope antigen vaccines. Received: 27 December 1999 / Accepted: 27 January 2000     

治疗性疫苗的研究进展

治疗性疫苗可克服机体的免疫耐受 ,提高机体的特异性免疫反应 ,对一些目前尚无有效治疗药物的传染性疾病及肿瘤等起到治疗作用。介绍了治疗性疫苗的概况、机理和临床研究的最新进展。     

新型疫苗佐剂的研究进展

与传统的灭活或活体疫苗相比,由基因工程重组抗原或化学合成多肽组成的现代疫苗往往存在免疫原性弱等问题,需要新型的免疫佐剂来增强其作用。尽管传统的铝盐佐剂是目前唯一全球公认的人用佐剂,但存在激发细胞免疫应答能力差等不足,因此,需要研发更为安全有效的人用新型佐剂,尤其是安全无毒、能够刺激较强细胞免疫应答的佐剂,以及适合粘膜疫苗、DNA疫苗和癌症疫苗的免疫佐剂。分析阐述了新型佐剂研究状况和佐剂发展方向,并进一步对新型佐剂的临床前和临床试验研究以及已批准上市的新型疫苗佐剂进行了综述。     

Prevention of bubonic and pneumonic plague using plant-derived vaccines

Yersinia pestis, the causative agent of bubonic and pneumonic plague, is an extremely virulent bacterium but there are currently no approved vaccines for protection against this organism. Plants represent an economical and safer alternative to fermentation-based expression systems for the production of therapeutic proteins. The recombinant plague vaccine candidates produced in plants are based on the two most immunogenic antigens of Y. pestis: the fraction-1 capsular antigen (F1) and the low calcium response virulent antigen (V) either in combination or as a fusion protein (F1–V). These antigens have been expressed in plants using all three known possible strategies: nuclear transformation, chloroplast transformation and plant-virus-based expression vectors. These plant-derived plague vaccine candidates were successfully tested in animal models using parenteral, oral, or prime/boost immunization regimens. This review focuses on the recent research accomplishments towards the development of safe and effective pneumonic and bubonic plague vaccines using plants as bioreactors.     

Immunogenicity and virus-like particle formation of rotavirus capsid proteins produced in transgenic plants

The human pathogen, group A rotavirus, is the most prevalent cause of acute infantile and pediatric gastroenteritis worldwide, especially in developing countries. There is an urgent demand for safer, more effective and cheaper vaccines against rotavirus infection. Plant-derived antigens may provide an exclusive way to produce economical subunit vaccines. Virus-like particles, constituting viral capsid proteins without viral nucleic acids, are considered a far safer candidate compared with live attenuated viral vaccines. In this study, the rotavirus capsid proteins VP2, VP6 and VP7 were co-expressed in transgenic tobacco plants, and their expression levels, formation of rotavirus-like particles (RV VLPs) and immunogenicity were extensively studied. Quantitative real-time RT-PCR and Western blot analysis revealed that the expression level of vp6 was the highest while vp7 was expressed at the lowest levels. The RV VLPs were purified from transgenic tobacco plants and analyzed by electron microscopy and Western blot. Results indicated that the plant-derived VP2, VP6 and VP7 proteins self-assembled into 2/6 or 2/6/7 RV VLPs with a diameter of 60–80 nm. When orally delivered into mice with cholera toxin as an adjuvant, the total soluble protein extracted from transgenic tobacco plants induced rotavirus-specific antibodies comparable with those of attenuated rotavirus vaccines, while VP 2/6/7 induced higher serum IgG and fecal IgA titers compared with VP 2/6.     

Genomic expression libraries for the identification of cross-reactive orthopoxvirus antigens

Increasing numbers of human cowpox virus infections that are being observed and that particularly affect young non-vaccinated persons have renewed interest in this zoonotic disease. Usually causing a self-limiting local infection, human cowpox can in fact be fatal for immunocompromised individuals. Conventional smallpox vaccination presumably protects an individual from infections with other Orthopoxviruses, including cowpox virus. However, available live vaccines are causing severe adverse reactions especially in individuals with impaired immunity. Because of a decrease in protective immunity against Orthopoxviruses and a coincident increase in the proportion of immunodeficient individuals in today's population, safer vaccines need to be developed. Recombinant subunit vaccines containing cross-reactive antigens are promising candidates, which avoid the application of infectious virus. However, subunit vaccines should contain carefully selected antigens to confer a solid cross-protection against different Orthopoxvirus species. Little is known about the cross-reactivity of antibodies elicited to cowpox virus proteins. Here, we first identified 21 immunogenic proteins of cowpox and vaccinia virus by serological screenings of genomic Orthopoxvirus expression libraries. Screenings were performed using sera from vaccinated humans and animals as well as clinical sera from patients and animals with a naturally acquired cowpox virus infection. We further analyzed the cross-reactivity of the identified immunogenic proteins. Out of 21 identified proteins 16 were found to be cross-reactive between cowpox and vaccinia virus. The presented findings provide important indications for the design of new-generation recombinant subunit vaccines.